Global Influenza A Infections API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021 - Overview, Comparative Analysis of Marketed and Emerging Products, and Marketed & Emerging Therapies
DUBLIN, Jan. 31, 2019 /PRNewswire/ --
The "Influenza A Infections - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Influenza A Infections - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Influenza A Infections. The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.
Global API Manufacturers of Marketed Products for Influenza A Infections
Coverage of API manufacturers for Influenza A Infections marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' name along with their location.
Emerging Phase III products for Influenza A Infections
This report provides a comprehensive understanding of the emerging Phase III therapies for Influenza A Infections which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2021.
Scope
-- A review of the marketed products for Influenza A Infections including
their description, route of synthesis, regulatory milestones, forecasted
sales estimates till 2021 and API manufacturer details.
-- Patent information coverage of the marketed products including the
patent number, holder, grant and patent expiry details
-- API manufacturers for the marketed products with location details
-- Emerging Phase III product profiles for Influenza A Infections including
product description, developmental activities, licensors & collaborators
and chemical information
Reasons to Buy
-- API intelligence for marketed drugs for the indication and gaining
insights of API manufacturers
-- Evaluate the marketing status and patent details of products to exploit
opportunities for generic drug development
-- Design effective counter-strategies to gain competitive advantage by
identifying the key patent expiry details and exclusivity with respect
to the indication
-- Establish a comprehensive understanding of the emerging Phase III
products which can be future competitors in this space
Key Topics Covered:
1. Report Introduction
2. Influenza A Infections: Overview
-- Risk Factors
-- Causes
-- Symptoms
-- Pathophysiology
-- Prognosis
-- Diagnosis
-- Treatment
3. Comparative Analysis of Marketed and Emerging Products
4. Marketed Therapies
-- Product Description
-- Route of Synthesis
-- Mechanism of Action
-- Pharmacology
-- Pharmacodynamics
-- Pharmacokinetics
-- Adverse Reactions
-- Clinical Trials
-- Regulatory Milestones
-- Product Development Activities
-- United States
-- Europe
-- Historical Global Sales
-- Forecasted Global Sales
-- Patent Details
5. Emerging Therapies (Phase III)
-- Product Description
-- Research and Development
-- Product Development Activities
-- Forecasted Global Sales
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/53mh89/global_influenza?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
